First Over-the-Counter Daily Contraceptive Pill Released (2024)

The Society of Family Planning and the North American Society for Pediatric and Adolescent Gynecology endorse this Practice Advisory.

This Practice Advisory was developed by the American College of Obstetricians and Gynecologists.

Background

On March 4, 2024, the first daily over-the-counter oral contraceptive pill became available in the United States. The distribution process and its availability in stores and online will be an ongoing process, so availability initially may be limited. The U.S. Food and Drug Administration (FDA) approved Opill, a progestin-only (0.075-mg norgestrel) tablet, on July 13, 2023. This progestin-only pill (POP) is approved without a prescription for adolescents and adults to prevent pregnancy. The FDA did not approve this POP for menstrual suppression or other noncontraceptive indications. The FDA requires data to demonstrate that a medication can be safely switched to an over-the-counter product. Studies demonstrated that this medication can be used by consumers safely and effectively, relying only on the nonprescription drug labeling without any assistance from a health care professional 1 .

The Safety of Progestin-Only Pills

The American College of Obstetricians and Gynecologists (ACOG) has long supported over-the-counter access to oral contraception 2 . Both POPs and combination estrogen and progestin pills are associated with a lower risk of complications than those seen during pregnancy and the postpartum period. There are some conditions that are absolute or relative contraindications to POP use, including current or past breast cancer. See the Centers for Disease Control and Prevention’s U.S. Medical Eligibility Criteria for Contraceptive Use for more information 3 . Individuals with obesity can safely use POPs, so screening for obesity is not needed 4 . No examinations or tests, including pelvic examinations and cervical cancer screening, are needed prior to the initiation of POPs 4 , and the need for routine preventive health visits should not be used as a barrier to over-the-counter access to contraception. Additionally, data demonstrate that potential users of over-the-counter hormonal contraceptive pills are effectively able to self-screen for potential contraindications 2 .

Clinical Considerations

Current data support that the efficacy of POPs is similar to that of combined progestin–estrogen contraceptive pills. For both types of oral contraceptives, 9% of U.S. women during the first year of use will have an unintended pregnancy with typical use, and 0.3% with perfect use 5 . It is important that POPs are taken at the same time each day (within the same 3-hour window). Those who miss pills (see Box 1), experience adverse effects with POPs (such as irregular bleeding), or who prefer another method of contraception should talk to a clinician about potential alternative methods.

Box 1. Missed Pills

If you are more than 3 hours late taking your tablet or miss taking your tablet on 1 or more days:

  • Take 1 tablet immediately, as soon as you remember that you missed it.
  • Then go back to taking your daily tablet at your usual time.
  • Use a condom (or another barrier method) every time you have sex during the next 2 days (48 hours), because it takes 2 days for this product to start working again.

Data from U.S. Food and Drug Administration. Opill norgestrel tablets 0.075 mg daily oral contraceptive. Accessed February 23, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017031s041lbl.pdf

Progestin-only contraceptives are safe for use during the postpartum period and for those breastfeeding 3 . For those concerned about confidentiality or who may be a victim of contraceptive coercion ( 6 , 7 ), an over-the-counter purchase allows the user to bypass insurance and avoid potential disclosure from itemized explanation of benefits statements. The over-the-counter POP may be a good option for those in between contraceptive methods or who do not have immediate access to a clinician or prescription refills. When patients using an over-the-counter method present for care, clinicians may provide counseling on other effective contraceptive methods but should support patient desires to continue with an over-the-counter method, if it is preferred. For more information on POPs and other contraceptive methods, see ACOG’s patient education resources at https://www.acog.org/womens-health/healthy-living/birth-control.

As with all nonbarrier contraceptive methods, the over-the-counter POP does not protect against sexually transmitted infections. Clinicians should advise those who choose the over-the-counter POP to use male or female condoms consistently (dual method use) to decrease the risk of sexually transmitted infections, including human immunodeficiency virus.

Access and Cost

Cost is a common barrier to accessing contraception. While having a user-dependent hormonal method available over the counter is a key step toward increasing access to family planning, if consumers cannot afford to purchase it (in person or online), including buying multiple packs at once, then the method is not truly accessible. Historically, high out-of-pocket costs, deductibles, and copayments for contraception have limited contraceptive access, even for those with private health insurance. A switch to over-the-counter access should not add yet another barrier for someone who desires contraception. While insurers are not required to cover over-the-counter contraceptives without an accompanying prescription, several states have passed laws requiring state-regulated private health plans to cover certain over-the-counter methods (eg, emergency contraception and condoms) without a prescription and without cost-sharing 8 . To address disparities in reproductive health, policies for over-the-counter contraception should cover Opill without a prescription requirement and at no up-front cost to the user, regardless of payer.

Conclusion

For both adults and adolescents, over-the-counter access to oral contraceptives has the potential to reduce barriers and increase contraceptive access 9 . The American College of Obstetricians and Gynecologists affirms the safety of the progestin-only oral contraceptive pill and the appropriateness of its over-the-counter availability. Over-the-counter methods should be both accessible and affordable.

Resources

These materials are for information purposes only and are not meant to be comprehensive. Referral to external resources does not imply ACOG’s endorsement of the organization, the organization’s website, or the content of the resource. The resources may change without notice.

Please contact [emailprotected] with any questions.

References

  1. U.S. Food and Drug Administration. FDA approves first nonprescription daily oral contraceptive. FDA; 2023. Accessed February 23, 2024. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive.
    Article Locations:
  2. Over-the-counter access to hormonal contraception. ACOG Committee Opinion No. 788. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;134:e96-105. doi: 10.1097/AOG.0000000000003473
    Article Locations:

    Article LocationArticle Location

  3. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-103. doi: 10.15585/mmwr.rr6503a1.
    Article Locations:

    Article LocationArticle Location

  4. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-66. doi: 10.15585/mmwr.rr6504a1
    Article Locations:

    Article LocationArticle Location

  5. Glasier A, Sober S, Gasloli R, Goyal A, Laurora I. A review of the effectiveness of a progestogen-only pill containing norgestrel 75 µg/day. Contraception 2022;105:1-6. doi: 10.1016/j.contraception.2021.08.016
    Article Locations:

    Article Location

  6. Reproductive and sexual coercion. ACOG Committee Opinion No. 554. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:411-5. doi: 10.1097/01.AOG.0000426427.79586.3b
    Article Locations:

    Article Location

  7. Confidentiality in adolescent health care. ACOG Committee Opinion No. 803. American College of Obstetricians and Gynecologists. Obstet Gynecol 2020;135:e171-7. doi: 10.1097/AOG.0000000000003770
    Article Locations:

    Article Location

  8. Long M, Diep K, Sobel L, Salganicoff A. Considerations for covering over-the-counter contraception. Kaiser Family Foundation; 2023. Accessed February 23, 2024. Available at: https://www.kff.org/policy-watch/considerations-covering-over-the-counter-contraception/.
    Article Locations:

    Article Location

  9. Guillard H, Laurora I, Sober S, Karapet A, Brass EP, Glasier A. Modeling the potential benefit of an over-the-counter progestin-only pill in preventing unintended pregnancies in the U.S. Contraception 2023;117:7-12. doi: 10.1016/j.contraception.2022.10.006
    Article Locations:

    Article Location

The American College of Obstetricians and Gynecologists recognizes and supports the gender diversity of all patients who seek obstetric and gynecologic care. In original portions of this document, authors seek to use gender-inclusive language or gender-neutral language. When describing research findings, this document uses gender terminology reported by investigators. To review ACOG’s policy on inclusive language, see https://www.acog.org/clinical-information/policy-and-position-statements/statements-of-policy/2022/inclusive-language.

A Practice Advisory is a brief, focused statement issued to communicate a change in ACOG guidance or information on an emergent clinical issue (eg, clinical study, scientific report, draft regulation). A Practice Advisory constitutes ACOG clinical guidance and is issued only online for Fellows but may also be used by patients and the media. Practice Advisories are reviewed periodically for reaffirmation, revision, withdrawal or incorporation into other ACOG guidelines. This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org/clinical.

While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Publications of the American College of Obstetrician and Gynecologists are protected by copyright and all rights are reserved. The College’s publications may not be reproduced in any form or by any means without written permission from the copyright owner.

The American College of Obstetricians and Gynecologists (ACOG) is the nation’s leading group of physicians providing evidence-based obstetric and gynecologic care. As a private, voluntary, nonprofit membership organization of more than 60,000 members, ACOG strongly advocates for equitable, exceptional, and respectful care for all women and people in need of obstetric and gynecologic care; maintains the highest standards of clinical practice and continuing education of its members; promotes patient education; and increases awareness among its members and the public of the changing issues facing patients and their families and communities. www.acog.org

Topics

ContraceptionCounselingHormonal contraceptive agentsHormonal methodsOral contraceptivesProgestins

First Over-the-Counter Daily Contraceptive Pill Released (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Fredrick Kertzmann

Last Updated:

Views: 5462

Rating: 4.6 / 5 (46 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Fredrick Kertzmann

Birthday: 2000-04-29

Address: Apt. 203 613 Huels Gateway, Ralphtown, LA 40204

Phone: +2135150832870

Job: Regional Design Producer

Hobby: Nordic skating, Lacemaking, Mountain biking, Rowing, Gardening, Water sports, role-playing games

Introduction: My name is Fredrick Kertzmann, I am a gleaming, encouraging, inexpensive, thankful, tender, quaint, precious person who loves writing and wants to share my knowledge and understanding with you.